Abstract
AbstractPresent approaches to assess cancer treatments are often inaccurate, costly, and/or cumbersome. Functional testing platforms that use live tumor cells are a promising tool both for drug development and for identifying the optimal therapy for a given patient, i.e. precision oncology. However, current methods that utilize patient-derived cells from dissociated tissue typically lack the microenvironment of the tumor tissue and/or cannot inform on a timescale rapid enough to guide decisions for patient-specific therapy. We have developed a microfluidic platform that allows for multiplexed drug testing of intact tumor slices cultured on a porous membrane. The device is digitally-manufactured in a biocompatible thermoplastic by laser-cutting and solvent bonding. Here we describe the fabrication process in detail, we characterize the fluidic performance of the device, and demonstrate on-device drug-response testing with tumor slices from xenografts and from a patient colorectal tumor.
Publisher
Cold Spring Harbor Laboratory
Reference72 articles.
1. Herper M. The Truly Staggering Cost Of Inventing New Drugs. 2012.https://www.forbes.com/sites/matthewherper/2012/02/22/the-truly-staggering-cost-of-inventing-new-drugs-the-print-version/#325e9c7f25f8.
2. Prasad V , Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017; 10065.
3. The High Cost of Cancer Drugs and What We Can Do About It
4. Phase II and phase III failures: 2013–2015
5. BIO industry analysis. Clinical development success rates 2006-2015. Bio Ind Anal Rep 2016; : https://www.bio.org/sites/default/files/Clinical%2.